BR112012011332A2 - agentes direcionados para gadd45beta - Google Patents
agentes direcionados para gadd45betaInfo
- Publication number
- BR112012011332A2 BR112012011332A2 BR112012011332A BR112012011332A BR112012011332A2 BR 112012011332 A2 BR112012011332 A2 BR 112012011332A2 BR 112012011332 A BR112012011332 A BR 112012011332A BR 112012011332 A BR112012011332 A BR 112012011332A BR 112012011332 A2 BR112012011332 A2 BR 112012011332A2
- Authority
- BR
- Brazil
- Prior art keywords
- gadd45beta
- agents directed
- groups
- tetrapeptide
- tripeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0918579.4A GB0918579D0 (en) | 2009-10-22 | 2009-10-22 | Gadd45beta targeting agents |
GB0918579.4 | 2009-10-22 | ||
PCT/GB2010/001970 WO2011048390A2 (en) | 2009-10-22 | 2010-10-22 | Gadd45beta targeting agents |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012011332A2 true BR112012011332A2 (pt) | 2016-11-22 |
BR112012011332B1 BR112012011332B1 (pt) | 2022-07-05 |
Family
ID=41426579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012011332-1A BR112012011332B1 (pt) | 2009-10-22 | 2010-10-22 | Agentes direcionados para gadd45beta |
Country Status (14)
Country | Link |
---|---|
US (2) | US8993717B2 (pt) |
EP (2) | EP3178836B1 (pt) |
JP (2) | JP5961113B2 (pt) |
KR (1) | KR20120099440A (pt) |
CN (1) | CN102741269B (pt) |
AU (1) | AU2010309594B2 (pt) |
BR (1) | BR112012011332B1 (pt) |
CA (2) | CA2778236A1 (pt) |
GB (1) | GB0918579D0 (pt) |
IL (1) | IL219325B (pt) |
IN (1) | IN2012DN03310A (pt) |
MX (1) | MX357801B (pt) |
RU (2) | RU2016102083A (pt) |
WO (1) | WO2011048390A2 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
PL219569B1 (pl) | 2010-02-19 | 2015-05-29 | Peptaderm Spółka Z Ograniczoną Odpowiedzialnością | Cykliczne tetrapeptydy i ich zastosowanie |
GB201107118D0 (en) | 2011-04-27 | 2011-06-08 | Imp Innovations Ltd | Method of diagnosis and prognosis |
KR101745766B1 (ko) * | 2011-10-14 | 2017-06-09 | 서울대학교산학협력단 | 펩타이드 나노구조체 및 그 제조 방법 |
ES2766648T3 (es) * | 2011-10-28 | 2020-06-12 | Neostrata Company Inc | Derivados de N-acildipéptidos y sus usos |
US20150038541A1 (en) * | 2012-03-19 | 2015-02-05 | Aposignal Bioscience Llc | Composition and methods for cell modulation |
CN104817618B (zh) * | 2014-01-30 | 2018-07-03 | 陈光健 | 寡肽cd01及其制备方法和应用 |
CN104817616A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd02及其制备方法和应用 |
GB201414542D0 (en) * | 2014-08-15 | 2014-10-01 | Imp Innovations Ltd | Novel therapy |
CN109776652B (zh) * | 2019-01-30 | 2020-08-18 | 浙江省医学科学院 | 鳕鱼皮寡肽及其分离纯化方法和在制备ɑ-葡萄糖苷酶抑制剂及抗Ⅱ型糖尿病药物中的应用 |
RU2716258C1 (ru) * | 2019-07-30 | 2020-03-11 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Пептидный антагонист нмда-рецептора |
KR102417496B1 (ko) * | 2019-11-29 | 2022-07-06 | (주)수파드엘릭사 | 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물 |
WO2021194228A1 (ko) * | 2020-03-23 | 2021-09-30 | 주식회사 엘베이스 | 암의 예방 또는 치료용 약학적 조성물 |
KR102348728B1 (ko) * | 2020-03-23 | 2022-01-12 | 주식회사 엘베이스 | 암의 예방 또는 치료용 약학적 조성물 |
CN116096714A (zh) | 2020-06-10 | 2023-05-09 | 安力高医药股份有限公司 | 用于治疗冠状病毒、小核糖核酸病毒和诺罗病毒感染的抗病毒化合物 |
US20230159587A1 (en) * | 2021-03-22 | 2023-05-25 | L-Base Co., Ltd. | Pharmaceutical composition for preventing or treating cancer |
WO2022203219A1 (ko) * | 2021-03-22 | 2022-09-29 | 주식회사 엘베이스 | 암의 예방 또는 치료용 약학적 조성물 |
AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
IT202100023357A1 (it) * | 2021-09-09 | 2023-03-09 | Cheirontech S R L | Peptidi con attività anti-angiogenica |
WO2023043269A1 (ko) * | 2021-09-17 | 2023-03-23 | 주식회사 엘베이스 | 면역반응을 조절하기 위한 약학적 조성물 |
WO2023043261A1 (ko) * | 2021-09-17 | 2023-03-23 | 주식회사 엘베이스 | 항암제의 항암 효과 증진용 약학적 조성물 |
KR102494749B1 (ko) * | 2021-09-17 | 2023-02-06 | 주식회사 엘베이스 | 암 치료용 cage 저해제에 대한 반응자 특성화 방법 |
CN116350746B (zh) * | 2023-05-16 | 2024-03-22 | 海口桥水联合科技有限责任公司 | 沙丁鱼肽组合物在治疗过敏性鼻炎的药物中的应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
HU187461B (en) | 1981-10-22 | 1986-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for producing n-nitrozo-n-bracket-beta-chloroethyl-bracket closed-carbamoyl-peptides of citostatic activity |
CA1257199A (en) | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
DE3813989A1 (de) * | 1987-04-29 | 1988-11-10 | Hoechst Ag | Peptide mit phospholipase a(pfeil abwaerts)2(pfeil abwaerts)-hemmender wirkung |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
US5962270A (en) | 1996-02-06 | 1999-10-05 | Bionebraska, Inc. | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs |
US6737408B1 (en) * | 1997-08-07 | 2004-05-18 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
FR2774674B1 (fr) | 1998-02-10 | 2000-03-24 | Atochem Elf Sa | Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre |
US5993414A (en) | 1998-04-23 | 1999-11-30 | Medtronic, Inc. | Implantable device |
US20030162223A1 (en) * | 1999-10-22 | 2003-08-28 | Lowery David E. | Drosophila G protein coupled receptors, nucleic acids, and methods related to the same |
US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
CN1535264A (zh) | 2001-05-15 | 2004-10-06 | ������ҩ��ʽ���� | 精氨酸衍生物 |
CA2707767C (en) | 2001-07-13 | 2013-09-03 | Cms Peptides Patent Holding Company Limited | Biologically active peptides |
US7354898B2 (en) * | 2001-10-02 | 2008-04-08 | University Of Chicago | Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
CA2462638A1 (en) | 2001-10-02 | 2003-04-10 | University Of Chicago | Methods and compositions for modulating apoptosis |
CN1675374A (zh) | 2002-08-19 | 2005-09-28 | 阎云 | 肝脏疾病的治疗 |
CL2004000858A1 (es) | 2003-04-22 | 2005-04-22 | Avanir Pharmaceuticals | Peptidos que comprende una region acida, una lipofilica o aromatica y una basica, que participan en transporte inverso de colesterol, composicion farmaceutica que los contienen, util para el tratamiento o prevencion de hipercolesterolemia y/o aterosc |
US7084111B2 (en) * | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
WO2006049597A1 (en) * | 2004-10-27 | 2006-05-11 | Avanir Pharmaceuticals | Amino acid-derived compounds as modulators of the reverse cholesterol transport |
EP1836159B1 (en) | 2005-01-13 | 2013-04-10 | University Of Wollongong | Antibiotic binaphthyl derivatives |
WO2006086321A2 (en) | 2005-02-09 | 2006-08-17 | Helix Biomedix Inc. | Antimicrobial hexapeptides |
CA2604133C (en) * | 2005-04-07 | 2015-12-01 | Centre National De La Recherche Scientifique | Compounds useful as modulators of the proteasome activity |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US7951782B2 (en) * | 2005-09-29 | 2011-05-31 | Maruha Nichiro Seafoods, Inc | Composition effective to prevent or treat adult disease |
JP2007217358A (ja) * | 2006-02-17 | 2007-08-30 | Nippon Meat Packers Inc | 抗酸化性ペプチド |
WO2007117444A2 (en) * | 2006-03-31 | 2007-10-18 | Yinghe Hu | Protein detection by aptamers |
US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
EP2049137A4 (en) * | 2006-08-08 | 2013-05-01 | Univ California | SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES |
CN101153053B (zh) * | 2006-09-28 | 2012-02-01 | 中国医学科学院药物研究所 | 骨生肽、其制备方法和其药物组合物与用途 |
EP1964560A1 (en) | 2007-02-28 | 2008-09-03 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of inhibitors of the degradation of p27 for the treatment of cancer |
WO2009099677A2 (en) | 2008-02-08 | 2009-08-13 | Aileron Therapeutics, Inc. | Therapeutic peptidomimetic macrocycles |
GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
EP2390662A1 (en) | 2010-05-27 | 2011-11-30 | Erasmus University Medical Center Rotterdam | Molecular classification of multiple myeloma |
-
2009
- 2009-10-22 GB GBGB0918579.4A patent/GB0918579D0/en not_active Ceased
-
2010
- 2010-10-22 CN CN201080058254.9A patent/CN102741269B/zh active Active
- 2010-10-22 EP EP16185463.3A patent/EP3178836B1/en active Active
- 2010-10-22 IN IN3310DEN2012 patent/IN2012DN03310A/en unknown
- 2010-10-22 RU RU2016102083A patent/RU2016102083A/ru not_active Application Discontinuation
- 2010-10-22 US US13/502,781 patent/US8993717B2/en active Active
- 2010-10-22 MX MX2012004755A patent/MX357801B/es active IP Right Grant
- 2010-10-22 RU RU2012120905/04A patent/RU2577311C2/ru active
- 2010-10-22 WO PCT/GB2010/001970 patent/WO2011048390A2/en active Application Filing
- 2010-10-22 AU AU2010309594A patent/AU2010309594B2/en active Active
- 2010-10-22 JP JP2012534766A patent/JP5961113B2/ja active Active
- 2010-10-22 KR KR1020127013065A patent/KR20120099440A/ko not_active Application Discontinuation
- 2010-10-22 BR BR112012011332-1A patent/BR112012011332B1/pt active IP Right Grant
- 2010-10-22 EP EP10781977A patent/EP2491051A2/en not_active Withdrawn
- 2010-10-22 CA CA2778236A patent/CA2778236A1/en not_active Abandoned
- 2010-10-22 CA CA3034860A patent/CA3034860A1/en not_active Abandoned
-
2012
- 2012-04-22 IL IL219325A patent/IL219325B/en not_active IP Right Cessation
-
2015
- 2015-02-10 US US14/618,613 patent/US9518083B2/en active Active
-
2016
- 2016-03-25 JP JP2016060994A patent/JP2016166211A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2012120905A (ru) | 2013-11-27 |
CA3034860A1 (en) | 2011-04-28 |
RU2016102083A (ru) | 2018-11-20 |
JP2016166211A (ja) | 2016-09-15 |
CA2778236A1 (en) | 2011-04-28 |
BR112012011332B1 (pt) | 2022-07-05 |
US8993717B2 (en) | 2015-03-31 |
EP3178836B1 (en) | 2019-12-25 |
MX357801B (es) | 2018-07-25 |
IN2012DN03310A (pt) | 2015-10-23 |
CN102741269A (zh) | 2012-10-17 |
IL219325B (en) | 2019-02-28 |
US20120277164A1 (en) | 2012-11-01 |
EP2491051A2 (en) | 2012-08-29 |
MX2012004755A (es) | 2012-11-22 |
AU2010309594A1 (en) | 2012-05-17 |
RU2577311C2 (ru) | 2016-03-20 |
WO2011048390A2 (en) | 2011-04-28 |
EP3178836A1 (en) | 2017-06-14 |
JP2013508346A (ja) | 2013-03-07 |
WO2011048390A3 (en) | 2011-11-03 |
IL219325A0 (en) | 2012-06-28 |
CN102741269B (zh) | 2017-08-29 |
JP5961113B2 (ja) | 2016-08-02 |
GB0918579D0 (en) | 2009-12-09 |
US9518083B2 (en) | 2016-12-13 |
KR20120099440A (ko) | 2012-09-10 |
US20150368294A1 (en) | 2015-12-24 |
AU2010309594B2 (en) | 2016-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012011332A2 (pt) | agentes direcionados para gadd45beta | |
SMT201600398B (it) | Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi | |
ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
CY1118038T1 (el) | Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος | |
EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
DOP2011000274A (es) | Proteinas de union a il-17 | |
EP2528934A4 (en) | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF | |
CL2016001405A1 (es) | A peptide mixture | |
PH12014500053A1 (en) | Proteasome inhibitors | |
EA200802184A1 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
EA201101522A1 (ru) | Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10) | |
GT200600240A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
CR11042A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2008000348A1 (es) | Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis. | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
CL2008001234A1 (es) | Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer. | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
EA201270722A1 (ru) | Формы рифаксимина и их применение | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
CO6551683A2 (es) | Tratamiento para trastornos gastrointestinales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: IP2IPO INNOVATIONS LIMITED (GB) |
|
B25G | Requested change of headquarter approved |
Owner name: IP2IPO INNOVATIONS LIMITED (GB) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: IMPERIAL INNOVATIONS LTD (GB) Free format text: ANULADA A PUBLICACAO CODIGO 25.7 NA RPI NO 2649 DE 13/10/2021 POR TER SIDO INDEVIDA. |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: IMPERIAL INNOVATIONS LTD (GB) Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2648 DE 05/10/2021 POR TER SIDO INDEVIDA. |
|
B25D | Requested change of name of applicant approved |
Owner name: IP2IPO INNOVATIONS LIMITED (GB) |
|
B25G | Requested change of headquarter approved |
Owner name: IP2IPO INNOVATIONS LIMITED (GB) |
|
B25A | Requested transfer of rights approved |
Owner name: IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/10/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |